ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Age-Related Lamin B1 Deficiency Activates SLC7A11-Dependent Disulfidptosis to Impair Osteogenesis via Intercepting Mitochondrial Fission.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Senile osteoporosis (SOP) is an aging-related disease characterized by decreased bone mass and susceptibility to fracture. The pathological mechanism of SOP, which involves impaired osteogenesis of bone marrow-derived mesenchymal stem cells (MSCs), warrants further investigation to facilitate the development of novel therapeutic agents. In this study, we demonstrated that age-related lamin B1 (LMNB1) deficiency in SOP-MSCs led to lamina-associated domain (LAD) detachment, causing super-enhancer (SE) formation to effectively drive SLC7A11 expression. Elevated SLC7A11 expression activated disulfidptosis in SOP-MSCs, thereby resulting in disulfide bond formation in actin and subsequent cytoskeleton collapse. The disulfide-crosslinked actin-induced cytoskeleton disorganization further disrupted their binding with DRP1, inducing mitophagy and oxidative phosphorylation dysfunction by intercepting mitochondrial fission. The resulting mitochondrial disorders impaired the osteogenesis of SOP-MSCs, aggravating age-related bone loss in SOP. Moreover, we identified the FDA-approved drug naldemedine as a potent inhibitor of SLC7A11-dependent disulfidptosis through virtual molecular screening and confirmed its therapeutic potential for SOP. Our findings explore the connection among age-related LMNB1 deficiency, SLC7A11-dependent disulfidptosis and mitochondrial fission disruption in SOP-MSCs and reveal their roles in the molecular mechanism of impaired osteogenesis in SOP. These data contribute to a better understanding of SOP pathogenesis and provide insight into potential clinical treatments.
Indexed as
Identifiers
42850722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.